Trial Profile
A phase II randomized study of chemo-anticoagulation (gemcitabine-dalateparin) [gemcitabine + dalteparin sodium] vs chemotherapy alone (gemcitabine) for locally advanced and metastatic pancreatic adenocarcinoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 02 Aug 2005
Price :
$35
*
At a glance
- Drugs Dalteparin sodium (Primary)
- Indications Thromboembolism
- Focus Therapeutic Use
- 02 Aug 2005 New trial record.